Vanda Shares Move in Pre-Market Ahead of Nereus and Bysanti Data
Vanda Pharmaceuticals VNDA dipped in early premarket trade Thursday, off 0.5% at $6.15 before the bell. Shares closed at $6.18 on Wednesday, when the stock climbed 3.2%. Investors looked at the drugmaker’s latest investor meetings and balanced that with concerns about costs for new product launches. Vanda is shifting focus from regulatory wins to showing product sales now. The Washington company recently launched Nereus for motion-induced vomiting and Bysanti for schizophrenia and acute bipolar I disorder, putting them in a lineup with Fanapt, Hetlioz and Ponvory.